EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Recognition and management of organ-specific toxicities associated with enfortumab vedotin plus pembrolizumab and erdafitinib in locally advanced or metastatic urothelial carcinoma

María José Juan Fita, Urbano Anido, Luis Bataller, Guillermo de Velasco, José Ignacio Fernández-Vigo, Alfonso Gómez de Liaño, Onofre Sanmartín Jiménez, Álvaro Pinto

Cancer Treatment Reviews · 2026-12 · 151 · 103233

DOI: 10.1016/j.ctrv.2026.103233 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Treatment Reviews, 2026-12. Verfasst von María José Juan Fita und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Fundación Instituto Valenciano de Oncología, Profesor Beltrán Báguena 8, Valencia, 46009, Spain. Electronic address: …. Die Arbeit nennt 52 Literaturangaben. Gefördert von: Astellas Pharma Inc, Johnson and Johnson Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Adverse eventsEnfortumab vedotinErdafitinibLocally advanced urothelial carcinomaMetastatic urothelial carcinomaPembrolizumabToxicity management

Autor:innen und Institutionen

  • Department of Medical Oncology, Fundación Instituto Valenciano de Oncología, Profesor Beltrán Báguena 8, Valencia, 46009, Spain. Electronic address: mjjuan@fivo.org.
  • Department of Medical Oncology, Hospital Clínico Universitario de Santiago, Rúa da Choupana s/n, 15706 Santiago de Compostela, A Coruña, Spain.
  • Department of Neurology, Fundación Instituto Valenciano de Oncología, Department of Medicine, University of Valencia, Profesor Beltrán Báguena 8, Valencia, 46009, Spain. Electronic address: lbataller@fivo.org.
  • Department of Medical Oncology, Hospital Universitario 12 de Octubre, Avda. de Córdoba s/n, Madrid, 28041, Spain.
  • Department of Ophthalmology, Hospital Clínico San Carlos, San Carlos Health Research Institute (IdISSC), Profesor Martín Lagos s/n, Madrid, 28040, Spain.
  • Department of Medical Oncology, Complejo Hospitalario Universitario Insular-Materno Infantil, Avenida Marítima del Sur, s/n, 35016 Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.

Förderung

  • Astellas Pharma Inc
  • Johnson and Johnson Pharmaceuticals

Zitieren

APA

Juan Fita, M. J., Anido, U., Bataller, L., de Velasco, G., Fernández-Vigo, J. I., Gómez de Liaño, A., Sanmartín Jiménez, O., & Pinto, Á. (2026). Recognition and management of organ-specific toxicities associated with enfortumab vedotin plus pembrolizumab and erdafitinib in locally advanced or metastatic urothelial carcinoma. Cancer Treatment Reviews, 151, 103233. https://doi.org/10.1016/j.ctrv.2026.103233

Vancouver

Juan Fita MJ, Anido U, Bataller L, de Velasco G, Fernández-Vigo JI, Gómez de Liaño A, et al. Recognition and management of organ-specific toxicities associated with enfortumab vedotin plus pembrolizumab and erdafitinib in locally advanced or metastatic urothelial carcinoma. Cancer Treatment Reviews. 2026;151:103233. doi:10.1016/j.ctrv.2026.103233

BibTeX
@article{JuanFita2026,
  author = {Juan Fita, María José and Anido, Urbano and Bataller, Luis and de Velasco, Guillermo and Fernández-Vigo, José Ignacio and Gómez de Liaño, Alfonso and Sanmartín Jiménez, Onofre and Pinto, Álvaro},
  title = {Recognition and management of organ-specific toxicities associated with enfortumab vedotin plus pembrolizumab and erdafitinib in locally advanced or metastatic urothelial carcinoma},
  journal = {Cancer Treatment Reviews},
  year = {2026},
  volume = {151},
  pages = {103233},
  doi = {10.1016/j.ctrv.2026.103233}
}
Kostenlos starten →